Invivyd, Inc. (NASDAQ:IVVD) Shares Bought by Barclays PLC

Barclays PLC grew its stake in Invivyd, Inc. (NASDAQ:IVVD) by 179.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 117,973 shares of the company’s stock after buying an additional 75,780 shares during the quarter. Barclays PLC owned 0.10% of Invivyd worth $120,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in IVVD. State Street Corp lifted its stake in Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares in the last quarter. Duquesne Family Office LLC purchased a new stake in shares of Invivyd during the 2nd quarter worth $629,000. Renaissance Technologies LLC acquired a new position in shares of Invivyd during the second quarter worth $421,000. Finally, Bank of New York Mellon Corp purchased a new position in Invivyd in the second quarter valued at $263,000. 70.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 65,359 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73. Following the transaction, the director now directly owns 4,012,320 shares of the company’s stock, valued at approximately $1,885,790.40. This trade represents a 1.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is owned by insiders.

Invivyd Stock Performance

Invivyd stock opened at $0.42 on Friday. The stock has a 50-day simple moving average of $0.55 and a 200-day simple moving average of $0.87. The company has a market capitalization of $50.04 million, a P/E ratio of -0.21 and a beta of 0.64. Invivyd, Inc. has a fifty-two week low of $0.38 and a fifty-two week high of $5.20.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of Invivyd in a report on Friday, January 10th. Morgan Stanley dropped their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Finally, HC Wainwright reduced their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.